Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Taisho: Sales Down 1% for Pharma, Up 4.6% for Self-Med
November 15, 2010
- Korosho OKs Continued Sale of Mylotarg in Japan
November 15, 2010
- Eisai to Increase Market Share for Higher-Strength Aricept
November 15, 2010
- AZ Aims to Add Sales of ¥100 Bil. by 2015
November 8, 2010
- Invega for Schizophrenia, OneDuro Patch for Cancer Pain Approved: Janssen
November 8, 2010
- Shionogi to Jointly Develop New Cephem Antibiotics with GSK
November 8, 2010
- Daiichi Sankyo Wins Levofloxacin Patent Lawsuit in the US
November 8, 2010
- Non-Steroidal Eye Drop Nevanac Approved: Alcon
November 8, 2010
- Group of Clinicians Protests against Asahi Shimbun for Reports on Vaccine Clinical Trial
November 8, 2010
- Shionogi, Sawai Settle Patent Infringement Lawsuit for Flomox
November 8, 2010
- Anti-Histaminic Xyzal Approved: GSK
November 8, 2010
- Chugai Develops New Technology to Produce Reusable MAb
November 8, 2010
- Generics May Save ¥200 Mil. Per Month: Kyokaikenpo
November 8, 2010
- Revolade Approved for ITP: GSK
November 8, 2010
- Chugai Presents Data on Eldecalcitol from Japanese Patients
November 8, 2010
- Japan-India EPA Not Intended to Preferentially Treat Applications from Indian Companies: Korosho
November 8, 2010
- MINCLEA Approved for Pretreatment for Endoscopy: Nihon Pharma
November 8, 2010
- TAK-442 Fails to Show Efficacy in Multinational PII Trial: Takeda
November 8, 2010
- FDA Approves DSP's Schizophrenia Drug Lurasidone
November 8, 2010
- Lyrica Approved for Pain Due to Peripheral Neuropathy: Pfizer Japan
November 8, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…